Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin plus G-CSF in cancer patients

被引:7
|
作者
Joshi, SS
Miller, K
Jackson, JD
Warkentin, P
Kessinger, A
机构
[1] Univ Nebraska, Med Ctr 986395, Dept Cell Biol & Anat, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
[3] Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE 68198 USA
[4] Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
关键词
erythropoietin; G-CSF blood stem cells; mobilization; cytotoxic effector cell; functions; phenotypes;
D O I
10.1080/146532400539017
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background Although the recombinant granulocyte colony-stimulating factor (G-CSF) is a good CD34 cell mobilizer; the effects of G-CSF mobilization on the immune effector function of the individual is not always optimal. We studied the functional and phenotypic properties of peripheral blood stem cells (PBSC) collected from 15 cancer patients mobilized with G-CSF plus recombinant erythropoietin (EPO). Methods The patients received EPO (300 U/kg) and (G-CSF 10 mu g/kg) per day as mobilizing cytokines and an autologous graft product was collected with at least daily apheresis procedures until a target number of CD34 cells and mononuclear cells were obtained Mononuclear cells from the first four PBSC collections were tested for their natural killer (NK), activated NK and lymphokine activated killer (LAK) cytotoxicity in vitro against K562 and Raji tumor target cells. Results There was a significant increase in NK, activated NK and LAK cytotoxicity in EPO + G-CSF mobilized cells when compared to mononuclear cells from premobilization blood baseline values Although there was no increase in CD3(+) T cells there was a significant increase in myeloid cells (CD14(+)), B-cells (CD20(+)) and NK cells (CD56(+)) following mobilization. There was no difference in T cell response to the mitogens PHA and Con-A, but there was an increase in B-cell response to PWM following mobilization. Thus, the combination of EPO + G-CSF not only mobilized hematopoietic precursor cells but also increased the number of immune effector cells in the PBSC collections.
引用
收藏
页码:15 / 24
页数:10
相关论文
共 50 条
  • [31] Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
    Buehler, Selina
    Akhoundova, Dilara
    Jeker, Barbara
    Legros, Myriam
    Seipel, Katja
    Daskalakis, Michael
    Bacher, Ulrike
    Pabst, Thomas
    CANCERS, 2023, 15 (02)
  • [32] Hematopoietic, Immune Recovery and Outcomes after Autologous Stem Cell Transplantation Following Plerixafor Plus G-CSF Versus Chemotherapy and G-CSF Based Mobilization in Pediatric Patients
    Choi, Jung Yoon
    Kang, Hyoung Jin
    Hong, Kyung Taek
    Hong, Che Ry
    Park, Kyung Duk
    Shin, Hee Young
    BLOOD, 2017, 130
  • [33] Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children (vol 2016, 4078215, 2016)
    Vazquez Meraz, Jose Eugenio
    Arellano-Galindo, Jose
    Martinez Avalos, Armando
    Mendoza-Garcia, Emma
    Jimenez-Hernandez, Elva
    STEM CELLS INTERNATIONAL, 2016, 2016
  • [34] The impact of G-CSF on mobilization and transplantation of peripheral blood stem cells (PBSC)
    Haas, R
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 319 - 319
  • [35] Stem Cell Mobilization With Plerixafor plus G-CSF In Comparison To Cyclophosphamide plus G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma
    Garfall, Alfred L.
    Dougherty, Andrew
    Vogl, Dan T.
    Weiss, Brendan M.
    Cohen, Adam D.
    Porter, David L.
    O'Doherty, Una
    Mangan, Patricia
    Cunningham, Kathleen
    Siegel, Don L.
    Stadtmauer, Edward A.
    BLOOD, 2013, 122 (21)
  • [36] Peripheral blood stem cell mobilization by G-CSF in related donors.
    Richter, E
    Eichler, H
    Raske, D
    Herrmann, D
    Blau, W
    Kerowgan, M
    Fauser, AA
    Goldmann, SF
    BONE MARROW TRANSPLANTATION, 1998, 21 : S193 - S193
  • [37] Comparison between mobilization with G-CSF versus G-CSF plus cyclophosphamide based chemotherapy in patients with breast cancer
    Arbona, C
    Mena, F
    Prosper, F
    Benet, I
    Lluch, A
    Garcia-Conde, J
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 780 - 780
  • [38] EFFICACY OF BIOSIMILAR G-CSF VERSUS ORIGINATOR G-CSF IN PERIPHERAL BLOOD STEM CELL MOBILIZATION IN de novo MULTIPLE MYELOMA PATIENTS
    Moscato, T.
    Recchia, A. G.
    Fedele, R.
    Neri, S.
    Gentile, M.
    Alati, C.
    Vincelli, I. O.
    Piro, E.
    Penna, G.
    Musolino, C.
    Ronco, F.
    Molica, S.
    Morabito, F.
    Martino, M.
    HAEMATOLOGICA, 2015, 100 : 32 - 32
  • [39] Peripheral blood stem cell mobilization in multiple myeloma (MM): High-dose cyclophosphamide plus G-CSF vs. G-CSF alone
    Goldschmidt, H
    Hegenbart, U
    Cremer, FW
    Kiel, K
    Moos, M
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 72 - 72
  • [40] Efficient mobilisation of peripheral blood stem cells (PBSC) with HiDAC plus Amsacrine plus G-CSF but not with mini-ICE plus G-CSF in patients with AML
    Hoglund, M
    Brune, M
    Sallerfors, B
    Ahlgren, T
    Billstrom, R
    Hedenus, M
    Markevarn, B
    Simonsson, B
    Stockelberg, D
    Wahlin, A
    BLOOD, 2001, 98 (11) : 177A - 177A